Niklas Korsbo

Niklas Korsbo

Auto-generated profile, based on publicly available information

Niklas Korsbo

Pumas AI Annapolis Maryland USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2021 in Science
Verified
Journal Article
Closed access
PDF file
WYWeibing Yang
Weibing Yang
SCSandra Cortijo
Sandra Cortijo
NKNiklas Korsbo
Niklas Korsbo
PRPawel Roszak
Pawel Roszak
KSKatharina Schiessl
Katharina Schiessl
EMElliot Meyerowitz
Elliot Meyerowitz
Cell cycle regulation: The hormone cytokinin regulates various aspects of plant development and physiology, largely by managing cell proliferation. Yang et al. show that cytokinin promotes nuclear localization of the transcription factor MYB3R4, which activates the expression of two importins and genes that tip the cell into the next phase of the cell cycle. The importins facilitate further MYB3R4 accumulation within the nucleus, accelerating the progression into mitosis. MYB3R4 and the importins dissipate when the nuclear membrane dissolves at prometaphase, so there is only one round of mitotic activation per cell cycle. Science , this issue p. 1350

19 February 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KFKateryna Fal
Kateryna Fal
NKNiklas Korsbo
Niklas Korsbo
JAJuan Alonso-Serra
Juan Alonso-Serra
JTJose Teles
Jose Teles
MLMengying Liu
Mengying Liu
OHOlivier Hamant
Olivier Hamant
Artificial mechanical perturbations affect chromatin in animal cells in culture. Whether this is also relevant to growing tissues in living organisms remains debated. In plants, aerial organ emergence occurs through localized outgrowth at the periphery of the shoot apical meristem, which also contains a stem cell niche. Interestingly, organ outgrowth has been proposed to generate compression in the saddle-shaped organ–meristem boundary domain. Yet whether such growth-induced mechanical stress affects chromatin in plant tissues is unknown. Here, by imaging the nuclear envelope in vivo over time and quantifying nucleus deformation, we demonstrate the presence of active nuclear compression in that domain. We developed a quantitative pipeline amenable to identifying a subset of very deformed nuclei deep in the boundary and in which nuclei become gradually narrower and more elongated as the cell contracts transversely. In this domain, we find that the number of chromocenters is reduced, as shown by chromatin staining and labeling, and that the expression of linker histone H1.3 is induced. As further evidence of the role of forces on chromatin changes, artificial compression with a MicroVice could induce the ectopic expression of H1.3 in the rest of the meristem. Furthermore, while the methylation status of chromatin was correlated with nucleus deformation at the meristem boundary, such correlation was lost in the h1.3 mutant. Altogether, we reveal that organogenesis in plants generates compression that is able to have global effects on chromatin in individual cells. Significance During development, growth deforms tissues and organs. This is notably the case during the formation of new flowers in plants, as the tissue folds during young floral bud emergence. Here, we provide further evidence that organogenesis compresses the cells at the boundary, separating the organ from the stem cell niche, and we show that this leads to nucleus compression and chromatin changes. While mechanical forces are well known to affect nucleus shape and chromatin in mammalian cells in culture, this demonstrates that such an effect also occurs in a developing organism and suggests that forces may help to define boundary domains through large-scale chromatin effects.

29 June 2020 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
NKNiklas Korsbo
Niklas Korsbo
HJHenrik Jönsson
Henrik Jönsson
Thoughtful use of simplifying assumptions is crucial to make systems biology models tractable while still representative of the underlying biology. A useful simplification can elucidate the core dynamics of a system. A poorly chosen assumption can, however, either render a model too complicated for making conclusions or it can prevent an otherwise accurate model from describing experimentally observed dynamics. Here, we perform a computational investigation of sequential multi-step pathway models that contain fewer pathway steps than the system they are designed to emulate. We demonstrate when such models will fail to reproduce data and how detrimental truncation of a pathway leads to detectable signatures in model dynamics and its optimised parameters. An alternative assumption is suggested for simplifying such pathways. Rather than assuming a truncated number of pathway steps, we propose to use the assumption that the rates of information propagation along the pathway is homogeneous and, instead, letting the length of the pathway be a free parameter. We first focus on linear pathways that are sequential and have first-order kinetics, and we show how this assumption results in a three-parameter model that consistently outperforms its truncated rival and a delay differential equation alternative in recapitulating observed dynamics. We then show how the proposed assumption allows for similarly terse and effective models of non-linear pathways. Our results provide a foundation for well-informed decision making during model simplifications. Mathematical modelling can be a highly effective way of condensing our understanding of biological processes and highlight the most important aspects of them. Effective models are based on simplifying assumptions that reduce complexity while still retaining the core dynamics of the original problem. Finding such assumptions is, however, not trivial. In this paper, we explore ways in which one can simplify long chains of simple reactions wherein each step is only dependent on its predecessor. After generating synthetic data from models that describe such chains in explicit detail we compare how well different simplifications retain the original dynamics. We show that the most common such simplification, which is to ignore parts of the chain, often renders models unable to account for time delays. However, we also show that when such a simplification has had a detrimental effect it leaves a detectable signature in its optimised parameter values. We also propose an alternative assumption which leads to a highly effective model with only three parameters. By comparing the effects of these simplifying assumptions in thousands of different cases and for different conditions we are able to clearly show when and why one is preferred over the other.

13 November 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
APAna Victoria Ponce‐Bobadilla
Ana Victoria Ponce‐Bobadilla
DBDominic Bräm
Dominic Bräm
AFAli Farnoud
Ali Farnoud
Holger FröhlichHolger Fröhlich
Holger Fröhlich
AJAlexander Janssen
Alexander Janssen
SMSven Mensing
Sven Mensing

1 January 2026 in Quantitative Medicine
Verified
Journal Article
Open access
PMPatrick Kofod Mogensen
Patrick Kofod Mogensen
ANAndreas Noack
Andreas Noack
MTMohamed Tarek
Mohamed Tarek
CEChris Elrod
Chris Elrod
DMDavid Müller-Widmann
David Müller-Widmann
VIVijay Ivaturi
Vijay Ivaturi
Pumas (Pharmaceutical Modeling and Simulation) is a software ecosystem for quantitative pharmaceutical analytics built on the Julia programming language. The use of “pharmaceutical modeling” is deliberate. Pumas is designed as a unified platform for quantitative analytics across the full horizontal of drug development. The classical pharmacometrics segment; non-compartmental analysis, population PK/PD, quantitative systems pharmacology, physiologically based pharmacokinetic modeling, bioequivalence, and in-silico clinical trials represents one part of this continuum. Pumas extends this to machine learning–augmented pharmacology (DeepPumas), epidemiological modeling, pharmacoeconomics, quality-by-design, clinical trial design and optimization, precision dosing, real-world evidence analytics, and many more. While only a subset of these capabilities has been released to date, the architectural vision is to serve the analytical needs of pharmaceutical R&D end-to-end, from target identification through regulatory submission and post-market surveillance. The term “pharmaceutical modeling” reflects this scope: not pharmacometrics alone, but the entirety of quantitative science that underpins modern drug development within a single scientific computing ecosystem. This article introduces the Pumas ecosystem and demonstrates its integrated workflow through a complete case study of a multiple ascending dose trial with pharmacokinetic (PK) and pharmacodynamic (PD) endpoints. At this moment, the platform integrates many related capability domains: Clinical Data Interchange Standards Consortium (CDISC)-compliant data preparation, exploratory data analysis with publication-quality visualization, non-compartmental analysis (NCA) with bioequivalence testing, nonlinear mixed effects (NLME) modeling with multiple estimation algorithms (e.g., First Order Conditional Estimation (FOCE), Laplacian, Stochastic Approximation Expectation Maximization (SAEM), Monte Carlo Expectation Maximization (MCEM), Bayesian), simulation with differential equations using a variety of solvers, machine learning integration via DeepPumas, optimal experimental design, parallel computing infrastructure, and automated reporting through Quarto integration. We demonstrate the unified workflow from data preparation through model-based dose selection. The example use case is chosen to be reasonably simple to focus on the workflow itself yet realistic enough to illustrate key concepts. Using a case study with 60 subjects across 6 dose levels, we develop a two-compartment pharmacokinetic model with covariate effects (sex on clearance, weight on volume), extend to pharmacodynamics with an indirect response model, and simulate alternative dosing regimens to evaluate target attainment metrics. The complete analysis executes within a single computational framework, eliminating tool-switching overhead and data conversion steps. Pumas’s design principles include multiple dispatch, composability, and performance that enable both rigorous statistical modeling and rapid iterative exploration. Integration across workflow stages reduces friction in pharmacometric analyses, supporting quantitative decision-making from first-in-human studies through regulatory submission. The platform supports Phase 1–3 clinical trial analysis and model-informed drug development applications.

19 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CMCarl Julius Martensen
Carl Julius Martensen
NKNiklas Korsbo
Niklas Korsbo
VIVijay Ivaturi
Vijay Ivaturi
SSSebastian Sager
Sebastian Sager
In pharmacometrics, developing and selecting models is crucial for quantitatively assessing drug-biological interactions, treatment planning, and gaining insights into underlying processes. These validated models are essential for predictive analytics and strategic decision-making in drug development and clinical practice. Unlike traditional methods, machine learning (ML) offers a data-driven alternative to conventional, first-principle approaches. This paper presents an automatic method to derive unknown or uncertain (sub)models using longitudinal, heterogeneous data. Initially, we employ deep nonlinear mixed effect (DeepNLME) to train a neural network as a universal approximator, which then generates a parameterized representation of the underlying process. Subsequently, we apply symbolic regression to identify a set of potential models expressed as equations. Within the study parameters, the proposed method outperforms the baseline models and demonstrates the validity of both the DeepNLME approach and the symbolic regression approach.